文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

年龄相关性黄斑变性伴或不伴有息肉样脉络膜血管病变患者接受光动力治疗后的两年视力结果。

Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions.

作者信息

Tsuchiya Daijiro, Yamamoto Teiko, Kawasaki Ryo, Yamashita Hidetoshi

机构信息

Department of Ophthalmology and Visual Science, Yamagata University Faculty of Medicine, Yamagata, Japan.

出版信息

Retina. 2009 Jul-Aug;29(7):960-5. doi: 10.1097/IAE.0b013e3181a3b7c5.


DOI:10.1097/IAE.0b013e3181a3b7c5
PMID:19491727
Abstract

PURPOSE: To describe the visual outcomes 2 years after photodynamic therapy in Japanese patients with age-related macular degeneration (AMD) with or without polypoidal choroidal vasculopathy (PCV) lesions. METHODS: Sixty-three eyes of 63 consecutive patients with AMD or AMD + PCV who underwent photodynamic therapy were included in this study. Fluorescein and indocyanine green angiography were performed to diagnose AMD and AMD + PCV. Change in mean visual acuity and recurrence of active lesion during the follow-up period up to 2 years were assessed. RESULTS: Patients with typical AMD maintained visual acuity for 2 years after photodynamic therapy. For patients with AMD + PCV, the visual acuity was maintained during the first year but started decreasing by 0.09 logarithm of the minimum angle of resolution units per 3 months (95% confidence intervals [CI], 0.06-0.14) after 1 year. Moreover, patients with AMD + PCV had 82% higher risk of a recurrence of active lesions for each increase in 3 months of follow-up time after 1 year; this suggested that the risk of recurrence had increased later in follow-up after 1 year. Recurrence of active PCV lesions and massive subretinal hemorrhages were the main reasons for the late worsening of visual acuity. CONCLUSION: The visual acuity after photodynamic therapy in AMD patients was maintained for 2 years after the initial treatment. Patients with AMD + PCV had stable visual outcome within 1 year but not after 1 year; there are risks of late recurrences and massive hemorrhages after 1 year in patients with AMD + PCV.

摘要

目的:描述接受光动力疗法的日本年龄相关性黄斑变性(AMD)患者(无论有无息肉样脉络膜血管病变(PCV))2年后的视力结果。 方法:本研究纳入了63例连续接受光动力疗法的AMD或AMD + PCV患者的63只眼。进行荧光素和吲哚菁绿血管造影以诊断AMD和AMD + PCV。评估了长达2年随访期内平均视力的变化和活动性病变的复发情况。 结果:典型AMD患者在光动力疗法后2年保持视力。对于AMD + PCV患者,视力在第一年保持稳定,但1年后开始以每3个月0.09最小分辨角对数单位下降(95%置信区间[CI],0.06 - 0.14)。此外,AMD + PCV患者在1年后每增加3个月的随访时间,活动性病变复发风险高82%;这表明随访1年后复发风险增加。活动性PCV病变复发和大量视网膜下出血是视力后期恶化的主要原因。 结论:AMD患者光动力疗法后的视力在初始治疗后2年保持稳定。AMD + PCV患者在1年内视力结果稳定,但1年后不稳定;AMD + PCV患者在1年后有后期复发和大量出血的风险。

相似文献

[1]
Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions.

Retina. 2009

[2]
Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan.

Ophthalmologica. 2009

[3]
One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.

Ophthalmology. 2008-1

[4]
Polypoidal choroidal vasculopathy in Taiwanese patients.

Ophthalmic Surg Lasers Imaging. 2009

[5]
Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration.

Am J Ophthalmol. 2009-7

[6]
Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration.

Ophthalmology. 2007-9

[7]
Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability.

Am J Ophthalmol. 2006-10

[8]
Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy.

Retina. 2010-6

[9]
Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.

Am J Ophthalmol. 2010-8-16

[10]
Polypoidal choroidal vasculopathy and late geographic hyperfluorescence on indocyanine green angiography.

Br J Ophthalmol. 2009-6

引用本文的文献

[1]
One-year efficacy of "rescue photodynamic therapy" for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovasculopathy refractory to anti-vascular endothelial growth factor therapy.

Graefes Arch Clin Exp Ophthalmol. 2022-6

[2]
Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Taiwan J Ophthalmol. 2019

[3]
One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data.

Int J Ophthalmol. 2019-1-18

[4]
The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.

Int J Mol Sci. 2018-9-3

[5]
Incidence and risk factors of massive subretinal hemorrhage in retinal angiomatous proliferation.

PLoS One. 2017-10-12

[6]
Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population.

Indian J Ophthalmol. 2016-12

[7]
Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.

Graefes Arch Clin Exp Ophthalmol. 2017-3

[8]
Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis.

Int J Ophthalmol. 2015-10-18

[9]
Polypoidal choroidal vasculopathy: an update on therapeutic approaches.

J Ophthalmic Vis Res. 2013-10

[10]
Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy.

Br J Ophthalmol. 2013-2-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索